Mair Therapeutics
Therapeutics for neurodegenerative diseases targeting lysosomal ion channels.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Seed | |
| Total Funding | 000k | ||
Mair Therapeutics is a Dutch biotechnology startup developing treatments for neurodegenerative disorders, with an initial focus on Parkinson's disease. Launched in February 2025 with pre-seed funding from Torrey Pines Investment and Oost NL, the company is headquartered in Nijmegen, Netherlands, a region known for its strong Parkinson's research community. The company was founded by a team including CEO Dr. Vasily Kazey, a neuroscientist with 20 years of experience in drug discovery and biotech, and VP of MedChem Dr. Alexei Pushechnikov, a scientific leader with over two decades of experience in medicinal chemistry.
Mair Therapeutics' core scientific approach is centered on the modulation of TMEM175, a lysosomal ion channel critical for cellular waste management. In neurodegenerative diseases like Parkinson's, the accumulation of toxic protein aggregates, such as α-synuclein, is linked to lysosomal dysfunction. The company's strategy is to discover compounds that regulate TMEM175 to restore the lysosome's ability to clear this waste, thereby addressing a root cause of the disease. To accelerate the identification of potential therapeutics, Mair utilizes advanced computational modeling and drug discovery technologies, supported by the Expert Systems accelerator. The company also collaborates with academic institutions, including the Kuijpers Lab at Radboud University's Donders Institute.
Keywords: neurodegenerative diseases, Parkinson's disease, drug discovery, biotechnology, lysosomal ion channel, TMEM175, protein aggregation, α-synuclein, computational modeling, small-molecule drugs, therapeutics, ion channel modulation, pre-seed funding, Nijmegen, Torrey Pines Investment, Oost NL, Vasily Kazey, Alexei Pushechnikov